FibroGen Files 8-K: Shareholder Vote & Financials Update

TL;DR

FibroGen filed an 8-K for shareholder votes and financials. Details TBD.

AI Summary

FibroGen, Inc. filed an 8-K on June 7, 2024, reporting a submission of matters to a vote of security holders and financial statements/exhibits as of June 5, 2024. The filing does not contain specific details about the vote or financial information within the provided text.

Why It Matters

This filing indicates important corporate actions are being taken, potentially affecting shareholder rights and the company's financial standing.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose new material risks or significant financial events.

Key Players & Entities

• FibroGen, Inc. (company) — Registrant
• June 05, 2024 (date) — Earliest event reported
• June 7, 2024 (date) — Filing date
• 415-978-1200 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value FGEN The Nasdaq Global Se

Filing Documents

• fgen-20240605.htm (8-K) — 49KB
• fgen-ex10_1.htm (EX-10.1) — 237KB
• 0000950170-24-070636.txt ( ) — 431KB
• fgen-20240605.xsd (EX-101.SCH) — 23KB
• fgen-20240605_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. At the 2024 annual meeting of stockholders of FibroGen, Inc. ("FibroGen" or the "Company") held on June 5, 2024, the stockholders voted on the five proposals listed below. The proposals are described in detail in the Company's definitive proxy statement for the 2024 annual meeting of stockholders, filed with the Securities and Exchange Commission on April 24, 2024. The results of the matters voted upon at the meeting were: (1) All of the Class I nominees of the board of directors were elected to hold office until the Company's 2027 annual meeting of stockholders. The nominees were: (i) Thane Wettig: 54,857,819 shares of Common Stock voted for, 428,789 withheld, and 17,738,031 broker non-votes; (ii) James A. Schoeneck: 53,143,223 shares of Common Stock voted for, 2,143,385 withheld, and 17,738,031 broker non-votes; and (iii) Maykin Ho, Ph.D.: 53,617,649 shares of Common Stock voted for, 1,668,959 withheld, and 17,738,031 broker non-votes. The term of office of Class II directors Suzanne Blaug, Benjamin Cravatt, Ph.D., and Jeffrey L. Edwards continues until the Company's 2025 annual meeting of stockholders. The term of office of Class III directors Aoife Brennan, M.B., B.Ch. and Gerald Lema, continues until the Company's 2026 annual meeting of stockholders. (2) The stockholders approved the FibroGen, Inc. 2024 Equity Incentive Plan, attached hereto as Exhibit 10.1: 44,331,918 shares of Common Stock voted for, 10,837,159 against, and 117,531 abstaining. (3) The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2024 definitive proxy statement filed on April 24, 2024: 53,461,963 shares of Common Stock voted for, 1,754,540 against, and 70,105 abstaining. (4) The stockholders ratified the selection of PricewaterhouseCoopers LLP, by the Audit Committee of the FibroGen board of directors, as the independent registered p

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 FibroGen, Inc. 2024 Equity Incentive Plan. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. FibroGen, Inc. Date: June 7, 2024 By: /s/ Michael Lowenstein Michael Lowenstein Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR